Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YiQiFuMai Injection as an Adjunctive Treatment for Sepsis
NCT05265130Phase 4Unknown
- Sponsor
- Xiyuan Hospital
- Start
- Feb 2022
- Primary completion
- Jan 2024
- Modality
- HM (Herbal Medicine)
01
Overview
Phase 4, randomised trial in sepsis comparing YQFM group with Placebo group (2 arms). Primary endpoints: All-cause Mortality at 28 days, Mortality in Intensive Care Unit at 14 days and 7 more. Status: unknown.
02
Drugs
yiqi fumai
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT05265130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05265130.